Immunovant (IMVT) traded down -2.37 % during a 24 hours period ending at 07:28 PM Central Europe on Monday 26th. One Immunovant stock can currently be bought for about USD 28.24 on popular exchanges. Current supply of Immunovant stocks is 206.6 mn. Immunovant has a current market capitalization of USD 5.9 bn and approximately USD 18.2 mn worth of Immunovant was traded on exchanges in the last 24 hours. Since last month end, Immunovant has traded -16.44 % down. Simple moving average of last 200 days is at USD 31.97. The highest price of past 52 weeks was recorded at USD 45.42 on 08/19/2026. 52 weeks low was at USD 21.05 on 10/28/2025.

Summary of the latest news for Immunovant

Immunovant Inc. is scheduled to announce its financial results for the quarter ending 30 September 2026 on 9 November 2026. Analyst consensus suggests the company will report a modest quarterly loss per share slightly lower than the loss recorded in the same period a year earlier. Revenue forecasts for the quarter remain unchanged from the previous year, indicating a flat performance. For the current fiscal year, analysts expect a continued net loss per share, a small improvement over the loss seen in the prior year, while year‑to‑date revenue projections are projected to remain flat. The company’s forthcoming disclosure will provide further clarity on its financial outlook and operational performance.

Here is how related stocks have performed in the past 24 hours:

  • Msa Safety (MSA) traded down -1.18 % and now trades at USD 183.09. Msa Safety has a market capitalisation of USD 7 bn. Current price/earnings ratio for Msa Safety is 22.76. MSA Safety Inc. reported that it has completed a series of independent laboratory assays for lithium samples taken from a Canadian drill program. The tests were performed by MSALABS, an independent facility, and confirmed the presence of lithium‑bearing material in the core. The company noted that the samples were collected and processed under a rigorous quality‑control regime, with chain‑of‑custody procedures and regular use of blanks and reference materials. MSA Safety stated that the results support the interpretation of a spodumene‑bearing pegmatite system and will be incorporated into future technical studies and resource modelling. The company emphasized that the assay data are part of a broader exploration effort and will help refine estimates of the project’s mineralisation. No financial or price information was included in the release.

  • Navan (NAVN) traded up 3.57 % and now trades at USD 26.91. Current market capitalisation for Navan is USD 7 bn.

  • Ringcentral (RNG) traded up 5 % and now trades at USD 87.8. Current market capitalisation for Ringcentral is USD 7 bn. Current price/earnings ratio for Ringcentral is 67.36. RingCentral Inc. has attracted renewed attention from institutional investors following a notable rise in its share price. A recent analysis on Seeking Alpha maintains that the stock remains undervalued, citing an accelerating operational trajectory and growing momentum within the company. The assessment highlights that the current market rally has yet to fully exploit the potential gains associated with RingCentral’s advancements.

  • Kirby (KEX) traded up 1.25 % and now trades at USD 133.87. Current market capitalisation for Kirby is USD 7 bn. Kirby has a current price to earnings ratio of 20.43.

  • Commvault (CVLT) traded up 0.93 % and now trades at USD 168.37. Current market capitalisation for Commvault is USD 7 bn. Commvault has a current price to earnings ratio of 109.45.

About Immunovant

Immunovant Inc is a biopharmaceutical company based in New York, United States. The company specializes in discovering and manufacturing drugs for patients with autoimmune diseases. Immunovant serves customers globally and can be accessed online through their website at www.immunovant.com . The stock of the company is traded on the Nasdaq.